How does adding brensocatib to the multimodal NCFBE toolkit mark a meaningful clinical advance, and based on WILLOW, ASPEN, and the FDA label, what role might this inflammation-reducing DPP-1 inhibitor play in managing the disease?

Name: How does adding brensocatib to the multimodal NCFBE toolkit mark a meaningful clinical advance, and based on WILLOW, ASPEN, and the FDA label, what role might this inflammation-reducing DPP-1 inhibitor play in managing the disease?
Uploaded: T00:00:00+00:00

CLICK HERE FOR CME CREDIT Back to Symposium

Created by

Presenter

Anne E. O’Donnell, MD

The Nehemiah and Naomi Cohen Chair in Pulmonary Disease ResearchProfessor of MedicineInterim Chair, Department of MedicineChief, Division of Pulmonary, Critical Care and Sleep MedicineGeorgetown University Medical Center/Medstar Georgetown ...